🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the UK / NCT05697861
Enrolling by invitation Observational

Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

NCT05697861 · tracked via the Priya Life Science UK tracker
Sponsor
Intellia Therapeutics
Phase
Observational
Started
2023-07-10
Last updated
2026-08-03

Condition(s) studied

Transthyretin-Related (ATTR) Familial Amyloid PolyneuropathyTransthyretin-Related (ATTR) Familial Amyloid CardiomyopathyWild-Type Transthyretin Cardiac Amyloidosis

Study summary

This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. A subject has completed or discontinued from an Intellia-sponsored clinical study in which a complete or partial dose of NTLA-2001 was received. 2. A subject has provided informed consent for the LTFU study. Exclusion Criteria: None

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Clinical Trial Site Paris France
Clinical Trial Site Auckland New Zealand
Clinical Trial Site Umeå Sweden
Clinical Trial Site London United Kingdom

More Intellia Therapeutics trials in the UK

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05697861 on ClinicalTrials.gov ↗ ← All trials in the UK